The Technical Analyst
Protara Therapeutics Inc [TARA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Protara Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.21% $2.73
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 31.21 mill |
| EPS: | -3.57 |
| P/E: | -0.760 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 11.43 mill |
| Avg Daily Volume: | 0.231 mill |
| RATING 2024-04-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.760 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.13x |
| Company: PE -0.760 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.01 (10.29%) $0.281 |
| Date: 2024-04-17 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.39 - 3.07 ( +/- 12.45%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-19 | Shefferman Jesse | Buy | 59 000 | Common Stock |
| 2024-01-19 | Shefferman Jesse | Sell | 7 803 | Common Stock |
| 2024-01-19 | Shefferman Jesse | Buy | 357 000 | Stock Option (Right to Buy) |
| 2024-01-19 | Bandari Jathin | Buy | 137 000 | Stock Option (Right to Buy) |
| 2024-01-19 | Bandari Jathin | Buy | 23 000 | Common Stock |
| INSIDER POWER |
|---|
| 91.92 |
| Last 95 transactions |
| Buy: 2 372 974 | Sell: 114 915 |
Forecast:
16:00 - $2.74
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.74
Forecast 2: 16:00 - $2.74
Forecast 3: 16:00 - $2.74
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.73 (-4.21% ) |
| Volume | 0.174 mill |
| Avg. Vol. | 0.231 mill |
| % of Avg. Vol | 75.36 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TARA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2024-04-05 08:04:00 - Press Release
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026 anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026
2024-04-05 08:02:00 - Press Release
Protara Therapeutics Announces Alignment With Fda On Registrational Path Forward For Iv Choline Chloride In Patients Dependent On Parenteral Nutrition
New york, april 05, 2024 (globe newswire) -- protara therapeutics, inc. (nasdaq: tara), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has reached alignment with the u.s. food and drug administration (fda) on a registrational path forward for intravenous (iv) choline chloride, an investigational phospholipid substrate replacement. the company had previously been pursuing an indication in intestinal failure-associated liver disease (ifald) and following feedback from fda, will now pursue a broader indication in patients on parenteral nutrition (pn) who are or may become unable to synthesize choline from oral or enteral nutrition sources...
2024-04-05 08:00:00 - Press Release
Protara Therapeutics Announces Positive Three-month Data From Tara-002 Clinical Program In Nmibc
New york, april 05, 2024 (globe newswire) -- protara therapeutics, inc. (nasdaq: tara), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive data from three-month evaluable carcinoma in situ (cis) patients treated across its ongoing clinical program of tara-002, the company's investigational cell-based therapy, in high-risk non-muscle invasive bladder cancer (nmibc), including bacillus calmette-guÉrin (bcg)-unresponsive, bcg-experienced and bcg-naÏve patient populations.
2024-03-13 08:00:00 - Press Release
Protara Therapeutics Announces Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
New york, march 13, 2024 (globe newswire) -- protara therapeutics, inc. (nasdaq: tara), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the full year and fourth quarter ended december 31, 2023 and provided a business update.
2024-02-28 08:00:00 - Press Release
Protara Therapeutics To Present At The Td Cowen 44th Annual Health Care Conference
New york, feb. 28, 2024 (globe newswire) -- protara therapeutics, inc. (nasdaq: tara), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the td cowen 44th annual health care conference on wednesday, march 6, 2024 at 9:50 am et in boston.
Latest News
2024-04-12 10:56:15 - Zacks Investment Research
Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now
Protara Therapeutics (TARA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2024-03-23 06:00:00 - InvestorPlace
3 Stocks That Could Help You Retire on a Private Island
If you want to strike it rich via stocks to help you retire on a private island, the reality is this: You probably can't go the buy-and-hold approach that legendary investors like Warren Buffett deploy. For one thing, that was a different time when the “American Dream” was accessible to any hardworking, industrious individual.
2024-02-28 08:00:00 - GlobeNewsWire
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:50 am ET in Boston.
2024-01-31 07:30:00 - GlobeNewsWire
Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
2023-09-05 07:30:00 - GlobeNewsWire
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:30 am ET in New York.
2023-03-01 08:00:00 - GlobeNewsWire
Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:
2023-02-02 08:00:00 - GlobeNewsWire
Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York.
2022-10-05 11:00:26 - InvestorPlace
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.
2022-08-16 07:14:04 - Benzinga
Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More
The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.
2022-04-11 11:17:17 - Zacks Investment Research
Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.